<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0011009'>Acute</z:hpo> <z:e sem="disease" ids="C0948755" disease_type="Disease or Syndrome" abbrv="">pulmonary failure</z:e> during remission induction therapy is a serious complication in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>To the authors' knowledge, the course and prognosis of such patients is not well known </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A total of 1541 patients referred for remission induction chemotherapy of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> were retrospectively reviewed </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A total of 120 (8%) patients developed <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0948755" disease_type="Disease or Syndrome" abbrv="">pulmonary failure</z:e> within 2 weeks of the initiation of chemotherapy; 87 of these patients (73%) died during remission induction, whereas 17 (14%) achieved a complete response </plain></SENT>
<SENT sid="4" pm="."><plain>The median survival among the 120 patients with early <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0948755" disease_type="Disease or Syndrome" abbrv="">pulmonary failure</z:e> was 3 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>Predictive factors for the development of early <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0948755" disease_type="Disease or Syndrome" abbrv="">pulmonary failure</z:e> by multivariate analysis were: male sex (P = .00038), <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> (P = .00003), poor performance status (P = .001), lung infiltrates at diagnosis (P = .000001), and <z:hpo ids='HP_0003259'>increased creatinine</z:hpo> (P = .000005) </plain></SENT>
<SENT sid="6" pm="."><plain>Patients who had 0 to 1, 2, 3, or 4 to 5 adverse factors were found to have estimated predictive incidences of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0948755" disease_type="Disease or Syndrome" abbrv="">pulmonary failure</z:e> of 3%, 13%, 23%, and 34%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Preventive approaches at the start of induction therapy in patients at high risk of <z:e sem="disease" ids="C0948755" disease_type="Disease or Syndrome" abbrv="">pulmonary failure</z:e> may improve the outcome of these patients </plain></SENT>
</text></document>